Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?
Andrew H Wei, Andrew W Roberts
Cancer Discovery | AMER ASSOC CANCER RESEARCH | Published : 2019
Awarded by National Health and Medical Research Council of Australia
A.W. Roberts is supported by a Practitioner Fellowship from the National Health and Medical Research Council of Australia (1079560).